首页> 美国卫生研究院文献>other >PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas
【2h】

PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas

机译:基于PCR的简单亚组经过验证可用于胶质瘤分类并在IDH突变胶质瘤中定义阴性的预后拷贝数畸变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genetic subgrouping of gliomas has been emphasized recently, particularly after the finding of isocitrate dehydrogenase 1 (IDH1) mutations. In a previous study, we investigated whole-chromosome copy number aberrations (CNAs) of gliomas and have described genetic subgrouping based on CNAs and IDH1 mutations. Subsequently, we classified gliomas using simple polymerase chain reaction (PCR)-based methods to improve the availability of genetic subgrouping. We selected IDH1/2 and TP53 as markers and analyzed 237 adult supratentorial gliomas using Sanger sequencing. Using these markers, we classified gliomas into three subgroups that were strongly associated with patient prognoses. These included IDH mutant gliomas without TP53 mutations, IDH mutant gliomas with TP53 mutations, and IDH wild-type gliomas. IDH mutant gliomas without TP53 mutations, which mostly corresponded to gliomas carrying 1p19q co-deletions, showed lower recurrence rates than the other 2 groups. In the other high-recurrence groups, the median progression-free survival (PFS) and overall survival (OS) of patients with IDH mutant gliomas with TP53 mutations were significantly longer than those of patients with IDH wild-type gliomas. Notably, most IDH mutant gliomas with TP53 mutations had at least one of the CNAs +7q, +8q, −9p, and −11p. Moreover, IDH mutant gliomas with at least one of these CNAs had a significantly worse prognosis than did other IDH mutant gliomas. PCR-based mutation analyses of IDH and TP53 were sufficient for simple genetic diagnosis of glioma that were strongly associated with prognosis of patients and enabled us to detect negative CNAs in IDH mutant gliomas.
机译:最近已经强调了神经胶质瘤的遗传分组,尤其是在发现异柠檬酸脱氢酶1(IDH1)突变后。在先前的研究中,我们调查了神经胶质瘤的全染色体拷贝数畸变(CNA),并描述了基于CNA和IDH1突变的遗传亚组。随后,我们使用基于简单聚合酶链反应(PCR)的方法对神经胶质瘤进行分类,以提高遗传分组的可用性。我们选择IDH1 / 2和TP53作为标记,并使用Sanger测序分析了237例成人幕上神经胶质瘤。使用这些标记,我们将神经胶质瘤分为与患者预后密切相关的三个亚组。这些包括没有TP53突变的IDH突变神经胶质瘤,有TP53突变的IDH突变神经胶质瘤和IDH野生型神经胶质瘤。没有TP53突变的IDH突变型神经胶质瘤,与携带1p19q共缺失的神经胶质瘤相对应,其复发率低于其他两组。在其他高复发组中,具有TP53突变的IDH突变神经胶质瘤患者的中位无进展生存期(PFS)和总体生存(OS)明显长于IDH野生型神经胶质瘤患者。值得注意的是,大多数具有 TP53 突变的IDH突变神经胶质瘤至少具有CNA + 7q,+ 8q,-9p和-11p之一。此外,至少有这些CNA的 IDH 突变神经胶质瘤的预后显着低于其他 IDH 突变神经胶质瘤。基于PCR的 IDH TP53 突变分析足以对神经胶质瘤进行简单的基因诊断,与患者的预后密切相关,使我们能够检测到中的CNA阴性IDH 突变型神经胶质瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号